Chelation therapy in β-thalassemia: An optimistic update

Seminars in Hematology

Volumn 38, Issue 4, 2001, Pages 360-366

  Giardina, Patricia J ^a   Grady, Robert W ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDROXYBENZOIC ACID; ASCORBIC ACID; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; HETASTARCH; IRON; IRON CHELATING AGENT; N,N' BIS(2 HYDROXYBENZYL)ETHYLENEDIAMINE N,N' DIACETIC ACID; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; ARTHROPATHY; BETA THALASSEMIA; CLINICAL TRIAL; DRUG POTENTIATION; ERYTHROCYTE TRANSFUSION; HUMAN; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; LIVER FIBROSIS; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW;

EID: 0034783438     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(01)90030-7     Document Type: Article

References (72)

1. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1)
2. Results of long-term deferiprone (L1): A report by the International Study Group on Oral Iron Chelators
3. A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload
4. Alternate use of deferiprone and desferrioxamine in primary school children with thalassemia major
5. Sequential use of deferiprone and desferrioxamine in primary school children with thalassaemia major in Turkey
6. Deferiprone: A review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases
7. HBED: A potential alternative to deferoxamine for iron-chelating therapy
8. HBED: The continuing development of a potential alternative to deferoxamine for iron-chelating therapy
9. Evaluation of a new method of administration of the iron chelating agent deferoxamine
10. Survival and disease complications in thalassemia major
11. Secondary iron overload disorders
12. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy
13. The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation
14. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major
15. Survival and morbidity in transfusion-dependent thalassemic patients on subcutaneous desferrioxamine chelation. Nearly two decades of experience
16. Current status of iron chelation therapy with deferoxamine
17. A multi-center safety trial of the oral iron chelator deferiprone
18. Safety profile of the oral iron chelator deferiprone: A multicentre study
19. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia
20. Oral iron chelation with deferiprone
21. Therapy for β-thalassemia - A paradigm for the treatment of genetic disorders
22. Results of long-term iron-chelating therapy
23. A depot formulation of desferrioxamine (ICL749B): Update on the dose-finding program
24. Chelation therapy in β-thalassemia: The benefits and limitations of desferrioxamine
25. Deferiprone: An effective iron "shuttle"
26. Optimizing chelation therapy: Combining deferiprone and desferrioxamine
27. Oral iron chelation: HBED may yet prove to be a very useful agent
28. Oral iron chelation: A potential role for HBED in combination therapy
29. HBED: A potential oral iron chelator
30. The combined use of 2,3-dihydroxybenzoic acid and desferrioxamine in iron chelation therapy
31. Preliminary results from a phase I clinical trial of HBED
32. The identification of 2,3-dihydroxybenzoic acid as a potentially useful iron-chelating drug
33. Iron chelators for thalassaemia
34. ICL670A: A new synthetic oral chelator: Evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture
35. Pathophysiology of iron overload
36. Design of orally active iron chelators
37. Oral iron chelation
38. Iron chelation: 2 better than 1?
39. Hoffbrand AV: Iron chelation therapy: The need for orally active drugs
40. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients
41. Diagnosis and management of iron-induced heart disease in Cooley's anemia
42. Iron-chelation therapy with oral deferiprone - Toxicity or lack of efficacy?
43. Evaluation of efficacy of L1 versus desferrioxamine by clinical randomized multicentric study
44. Long-term follow up of growth, bone, and cartilage abnormalities during chelation therapy with deferoxamine and deferiprone
45. An orally active iron chelator
46. Prospective on thalassemia
47. Long-term therapy with deferiprone
48. The β-thalassemias
49. Iron-chelating therapy and the treatment of thalassemia
50. Long-term trials of deferiprone in Cooley's anemia
51. Iron-chelation therapy with oral deferiprone in patients with thalassemia major
52. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major
53. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients
54. Survival in medically treated patients with homozygous β-thalassemia
55. The first prospective randomized trial of subcutaneous deferoxamine and the orally active iron chelating agent L1
56. Deferiprone (L1) associated neutropenia in beta thalassemia major: An Indian experience
57. Chelation studies with 2,3-dihydroxybenzoic acid in patients with β-thalassemia major
58. Chelation therapy in β-thalassemia major: A one-year double blind study of 2,3-dihydroxybenzoic acid
59. A novel oral iron chelator (ICL670A): Results of a phase I single-dose safety study
60. Oral iron chelators for the clinical management of iron overload. Current hopes and problems
61. Iron chelation therapy in the treatment of iron overload
62. Physiology and pathophysiology of iron metabolism: Implications for iron chelation therapy in iron overload
63. Evaluation of new iron chelators for clinical use
64. A trial to investigate the relationship between DFO pharmacokinetics and metabolism and DFO-related toxicity
65. The controversial role of deferiprone in the treatment of thalassemia
66. New trends in the treatment of beta-thalassemia
67. Chelator-induced iron excretion in iron-overloaded marmosets
68. Compliance with deferoxamine (DFO) in transfused patients: Influence of objective monitoring on control of body iron burden
69. Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine
70. Thalassemia in the next millennium. Keynote address
71. New approaches to the management of hepatitis and endocrine disorders in Cooley's anemia
72. Combined therapy with deferiprone and desferrioxamine